Moderna provided an update on its two planned research and manufacturing facilities at Shonan Health Innovation Park (iPark) in Fujisawa, Kanagawa Prefecture.

• Construction of the building for the mRNA drug research and manufacturing facility led by Moderna Enzymatics has been completed.

• Regarding the plan to develop an mRNA drug substance manufacturing facility led by Moderna Japan, after careful consideration given the current business environment, we have decided not to move forward with the plan at this time.

Moderna Enzymatics' cell-free DNA synthesis technology is a research support technology that dramatically improves the quality and speed of upstream mRNA manufacturing processes, and will continue to serve as an important foundation for supporting the development of innovative mRNA medicines.

The plan for the API manufacturing site led by Moderna Japan was adopted in 2023 as part of the Ministry of Economy, Trade and Industry's "Project to Develop Biopharmaceutical Manufacturing Bases to Strengthen Vaccine Production Systems," with the aim of establishing a domestic manufacturing system. However, in light of changes in the business environment both globally and in Japan, we have decided not to move forward with this plan at this time. We would like to express our sincere gratitude to the Ministry of Economy, Trade and Industry and all other parties involved for the tremendous support we have received in this endeavor.

Moderna continues to view business expansion in Japan as an important part of its strategy, and will reconsider establishing an mRNA drug manufacturing facility in the future if the business environment is favorable.

In addition, we will utilize our global manufacturing network to continue to provide a stable supply of vaccines to Japan, and will also promote the development of innovative treatments that utilize mRNA technology in areas with high unmet medical needs, such as vaccines for infectious diseases, as well as cancer and rare diseases.

We will continue to work with the Japanese government, local governments, medical professionals, and many other stakeholders to contribute to public health and the health of people in Japan.